• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

NEW DELHI: Ranbaxy Laboratories Ltd has received tentative approval from the US Food and Drug Administration (FDA) to manufacture and market Gabapentin tablets, 600 and 800 mg strengths used for the treatment of epilepsy and seizures.

The total sales for Gabapentin has been estimated to be $2.8 billion with Gabapentin tablets, 600 and 800 mg strengths, account for $1.1 billion share. Pfizer's Neurontin was dominating this segment.

In a statement, Mr Jim Meehan, Vice-President of Sales and Marketing for RPI, USA, said, "We are pleased to receive this tentative approval for Gabapentin tablets. This product represents a future opportunity, and we will launch Gabapentin tablets following final approval from the FDA."

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Sathavahana close to financial closure for greenfield project

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line